UBS Group Forecasts Strong Price Appreciation for Aveanna Healthcare (NASDAQ:AVAH) Stock

Aveanna Healthcare (NASDAQ:AVAH) had its price objective lifted by UBS Group from $9.50 to $10.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm presently has a “neutral” rating on the stock. UBS Group’s price target points to a potential upside of 6.41% from the company’s previous close.

Other research analysts have also recently issued reports about the stock. Weiss Ratings reiterated a “hold (c+)” rating on shares of Aveanna Healthcare in a research report on Monday, December 29th. Truist Financial lifted their target price on shares of Aveanna Healthcare from $9.50 to $10.00 and gave the stock a “hold” rating in a research report on Friday, November 7th. Royal Bank Of Canada upped their price target on shares of Aveanna Healthcare from $10.00 to $11.00 and gave the company a “sector perform” rating in a research report on Thursday. JPMorgan Chase & Co. raised Aveanna Healthcare from an “underweight” rating to a “neutral” rating and boosted their target price for the company from $6.00 to $10.00 in a research note on Thursday, September 18th. Finally, Jefferies Financial Group increased their target price on Aveanna Healthcare from $11.00 to $12.50 and gave the company a “buy” rating in a report on Tuesday, October 28th. Five analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $10.88.

Aveanna Healthcare Price Performance

Shares of AVAH traded up $0.06 during trading hours on Thursday, reaching $9.40. 140,331 shares of the company’s stock traded hands, compared to its average volume of 1,275,266. Aveanna Healthcare has a 12 month low of $3.67 and a 12 month high of $10.32. The company has a current ratio of 1.23, a quick ratio of 1.23 and a debt-to-equity ratio of 140.39. The stock has a market cap of $1.96 billion, a PE ratio of 26.11 and a beta of 2.06. The firm’s 50 day simple moving average is $8.80 and its 200-day simple moving average is $7.72.

Aveanna Healthcare (NASDAQ:AVAH) last announced its earnings results on Thursday, November 6th. The company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.07 by $0.08. Aveanna Healthcare had a net margin of 3.29% and a negative return on equity of 143.55%. The business had revenue of $621.94 million for the quarter, compared to the consensus estimate of $578.57 million. Equities analysts expect that Aveanna Healthcare will post -0.06 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Jeff Shaner sold 29,357 shares of Aveanna Healthcare stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $7.85, for a total value of $230,452.45. Following the transaction, the chief executive officer owned 2,394,179 shares in the company, valued at $18,794,305.15. This trade represents a 1.21% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Edwin C. Reisz sold 17,613 shares of the stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $7.85, for a total transaction of $138,262.05. Following the completion of the sale, the insider directly owned 1,321,114 shares of the company’s stock, valued at approximately $10,370,744.90. This trade represents a 1.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 32,857,606 shares of company stock valued at $295,491,307 in the last three months. Company insiders own 7.80% of the company’s stock.

Institutional Trading of Aveanna Healthcare

Institutional investors and hedge funds have recently made changes to their positions in the business. Summit Partners L P acquired a new stake in shares of Aveanna Healthcare in the 2nd quarter valued at approximately $50,477,000. Vanguard Group Inc. lifted its position in shares of Aveanna Healthcare by 34.7% in the third quarter. Vanguard Group Inc. now owns 4,041,659 shares of the company’s stock valued at $35,850,000 after buying an additional 1,041,324 shares during the last quarter. AustralianSuper Pty Ltd bought a new position in Aveanna Healthcare in the 3rd quarter valued at about $15,743,000. Connor Clark & Lunn Investment Management Ltd. grew its position in Aveanna Healthcare by 70.1% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,130,912 shares of the company’s stock worth $10,031,000 after buying an additional 466,022 shares in the last quarter. Finally, Algert Global LLC boosted its holdings in shares of Aveanna Healthcare by 120.1% in the 3rd quarter. Algert Global LLC now owns 1,022,599 shares of the company’s stock valued at $9,070,000 after purchasing an additional 557,898 shares in the last quarter. Institutional investors own 87.96% of the company’s stock.

About Aveanna Healthcare

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.